PET FDG Assessment of Change in Atherosclerotic Plaques After Chemotherapy

NCT00742352 | Unknown DMC

• 1 other identifier: TASMC-08-EES-253-CTIL
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine whether chemotherapy induces regression in atherosclerotic plaques in oncologic patients already undergoing PET FDG as part of their routine assessment.We will use PET FDG to assess whether the inflammation in atherosclerotic plaques is affected by chemotherapy and anti angiogenic therapy.

Conditions

Atherosclerosis

Study Arms (2)

Breast cancer patients

Lung cancer patients

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Breast cancer patients at the Tel-Aviv Sourasky Medical Center Lung cancer patients at the Tel-Aviv Sourasky Medical Center

You may qualify if:

• Women over the age of 65 diagnosed with metastatic breast cancer
• Men over the age of 65 diagnosed with lung cancer

You may not qualify if:

• Patients under the age of 65
• Patients diagnosed with chronic inflammatory disease or chronic infection
• Patients taking steroids and NSAIDS on a regular basis

Sponsors & Collaborators

• Tel-Aviv Sourasky Medical Center: lead

Study Sites (1)

Tel-Aviv Sourasky Medical Center

Tel Aviv, 64239, Israel

Location

MeSH Terms

Conditions

Atherosclerosis

Condition Hierarchy (Ancestors)

Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases

Central Study Contacts

Einat Even Sapir, MD PhD

CONTACT

972-3-6973532; evensap@tasmc.health.gov.il

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV

Study Record Dates

• First Submitted: August 25, 2008
• First Posted: August 27, 2008
• Study Start: September 1, 2008
• Last Updated: September 9, 2008

Record last verified: 2008-08

Locations

IL (1)